We treat the whole range of urological conditions and employ the latest proven techniques using the most up-to-date technology to provide timely and low-risk care for our patients.
Practising from London, Surrey, Hampshire and Berkshire, Urology Partners are a group of expert consultant urologists who offer a tailor made approach to your treatment, ensuring you get the best treatment for you and your condition. Our focus on minimally invasive procedures means short hospital stays and rapid return to normal activity. We treat the whole range of Urological Conditions for both men and women.
Professor Richard Hindley talks to Dr Francesca Kum about Rezum treatment for BPH, including the results of clinical trials and the patient experience since starting in 2017.
Andrew Chetwood discusses Urethral Strictures and the Optilume treatment now available
Urology Partners offer the complete portfolio of treatments for minimally invasive surgery to treat Benign Prostatic Hyperplasia (BPH)
With AI developing at such a pace, it was exciting to see it in action last week as part of prostate cancer diagnosis and the reporting of biopsy results.
We are delighted that Simon Bott was the first in the UK to use AI to interpet prostate biopsies pathology, working with Inify Laboratories at The Parkside Suite, Frimley Park Hospital, resulting in quicker and more accurate diagnostics.
The images below show the biopsy before and after AI interpretation. The image on the left shows the biopsy core and on the right, the highlighted pink and purple areas indicate the cancer cells
 |
 |
Screening for Prostate Cancer is an ever present topic, so it was great to have Simon Bott presenting at British Association of Urology Surgeons (BAUS) Conference last week in Manchester.
Funded by a grant from NHS England, and working with The Surrey and Sussex Cancer Alliance, the Targeted Prostate Health Check programme was set up to identify men from lower socio economic groups, and especially "at risk" groups, with prostate cancer and to offer PSA testing without burdening primary care. Of the 66,000 men identified, 21,905 took part.
Prostate Cancer was detected in 1.4% of men who had a PSA test. This worthwhile study has shown that we can undertake a targeted screening programme to identify clinically significant cancer, particularly in "at risk" men, without burdening GP services.
